Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors

被引:124
作者
Bilensoy, Erem [1 ]
Sarisozen, Can [1 ]
Esendagli, Guenes [2 ]
Dogan, A. Lale [2 ]
Aktas, Yesim [3 ]
Sen, Murat [4 ]
Mungan, N. Aydin [5 ]
机构
[1] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Inst Oncol, Dept Basic Oncol, TR-06100 Ankara, Turkey
[3] Ataturk Univ, Fac Pharm, Dept Pharmaceut Technol, TR-25240 Erzurum, Turkey
[4] Hacettepe Univ, Dept Chem, Div Polymer Chem, TR-06800 Beytepe, Turkey
[5] Zonguldak Karaelmas Univ, Fac Med, Dept Urol, TR-67600 Kozlu Zonguldak, Turkey
关键词
Mitomycin C; Chitosan; Poly-epsilon-caprolactone; Poly-L-lysine; Nanoparticle; Intravesical delivery; DRUG-DELIVERY; CANCER; MICROSPHERES; EFFICACY; CARRIERS; CHEMOTHERAPY; ALGINATE; SYSTEM;
D O I
10.1016/j.ijpharm.2008.12.015
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Cationic nanoparticles of chitosan (CS), poly-epsilon-caprolactone coated with chitosan (CS-PCL) and poly-e-caprolactone coated with poly-L-lysine (PLL-PCL) were developed to encapsulate intravesical chemotherapeutic agent Mitomycin C (MMC) for longer residence time, higher local drug concentration and prevention of drug loss during bladder discharge. Nanoparticle diameters varied between 180 and 340 nm depending on polymer used for preparation and coating. Zeta potential values demonstrated positive charge expected from cationic nanoparticles. MMC encapsulation efficiency depended on hydrophilicity of polymers since MMC is water-soluble. Encapsulation was increased by 2-fold for CS-PCL and 3-fold for PLL-PCL as a consequence of hydrophilic coating. Complete drug release was obtained with only CS-PCL nanoparticles. On the other hand, CS and PLL-PCL nanoparticles did not completely liberate MMC due to strong polymer-drug interactions which were elucidated with DSC studies. As far as cellular interaction was concerned, CS-PCL was the most efficient formulation for uptake of fluorescent markers Nile Red and Rhodamine123 incorporated into nanoparticles. Especially, CS-PCL nanoparticles loaded with Rhodamine123 sharing hydrophilic properties with MMC were selectively incorporated by bladder cancer cell line, but not by normal bladder epithelial cells. CS-PCL nanoparticles seem to be promising for MMC delivery with respect to anticancer efficacy tested against MB49 bladder carcinoma cell line. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 28 条
[1]
DEGRADATION OF MITOMYCIN-C IN ACIDIC SOLUTION [J].
BEIJNEN, JH ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 24 (2-3) :219-229
[2]
Targeted therapies in bladder cancer - an update [J].
Black, Peter C. ;
Agarwal, Piyush K. ;
Dinney, Colin P. N. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (05) :433-438
[3]
Influence of physicochemical and biological parameters on drug release from microspheres adhered on vesical and intestinal mucosa [J].
Bogataj, M ;
Mrhar, A ;
Korosec, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 177 (02) :211-220
[4]
Improving efficacy of intravesical chemotherapy [J].
Burgues Gasion, Juan Pablo ;
Jimenez Cruz, Juan Fernando .
EUROPEAN UROLOGY, 2006, 50 (02) :225-234
[5]
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers [J].
Calvo, P ;
VilaJato, JL ;
Alonso, MJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (01) :41-50
[6]
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[7]
2-4
[8]
Surface entrapment of polylysine in biodegradable poly(DL-lactide-co-glycolide) microparticles [J].
Cui, CJ ;
Schwendeman, SP .
MACROMOLECULES, 2001, 34 (24) :8426-8433
[9]
Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres [J].
De, SJ ;
Robinson, D .
JOURNAL OF CONTROLLED RELEASE, 2003, 89 (01) :101-112
[10]
Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer [J].
Eroglu, M ;
Irmak, S ;
Acar, A ;
Denkbas, EB .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 235 (1-2) :51-59